GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

GeoVax Labs, Inc. (Nasdaq: GOVX) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its malaria vaccine, titled, “Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria”.

David Dodd, GeoVax President and CEO, said, “We remain strongly committed to advancing innovation towards improving public health worldwide and this patent allowance reflects a potentially significant advancement relative to malaria prevention.”

According to data from the World Health Organization, malaria causes 227 million infections and 619,000 deaths worldwide each year.

Highlights

GeoVax’s GV-MVA-VLP™ vaccine platform utilizes modified vaccinia Ankara (MVA), a large virus capable of carrying several vaccine antigens, that expresses proteins that assemble into virus-like particles (VLP) immunogens in the person receiving the vaccine.

The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.

Share This Article

 

About the Author

GeoVax Receives Notice of Allowance for Malaria Vaccine Patent

Editor Prism MarketView